It's important to check with your health care provider to determine if participating in a clinical trial is right for you. Learn more about clinical trials, what questions to ask before participating and the drug approval process.
Clinical trials play an important role in the development of new and better treatments for psoriasis and psoriatic arthritis. Through clinical trials, companies can learn what treatments are safe and effective for psoriatic diseases, and possibly bring those drugs to the marketplace.
Are you concerned about inflammation elsewhere in your body? University Hospitals Case Medical Center is conducting a study to determine cardiovascular risk in patients 18-65 years old. Patients must have psoriasis covering > 10% body surface area. We will measure inflammatory blood markers at several time points and perform MRI of your blood vessels at baseline and one year. Your doctor will treat with the oral/biologic treatment of their choice. Patients will be compensated $425 for participating.
A randomized, double-blind, placebo and positive controlled, single and multiple dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of CJM112 in chronic plaque-type psoriasis patients.
Condition: Chronic Plaque-type Psoriasis | Phase: Phase 1/Phase 2 | Minimum Age: 18 Years
This study aims to see if patient quality of life can be approved after treatment with an injectable medication called ustekinumab for the treatment of generalized psoriasis. The investigators hypothesize that the investigators will see improvement in quality of life.
Condition: Psoriasis | Phase: Phase 4 | Minimum Age: 18 Years
The study aims to establish whether defects in immune cell function are shared across multiple autoimmune diseases and whether those problems match to similar genes in the cells.
Condition: Type 1 Diabetes Mellitus | Phase: N/A | Minimum Age: 8 Years
The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol compared to active comparator and placebo in adults with moderate to severe chronic plaque psoriasis.
Condition: Psoriasis | Phase: Phase 3 | Minimum Age: 18 Years
Psoriatic arthritis is a heterogeneous chronic inflammatory disorder involving joints, tendon sheaths, entheses, and the axial skeleton as well as skin and nails. This is an open-label trial with H.P. Acthar Gel (80 units/1mL) Subcutaneous injection administered twice weekly. To evaluate the signs and symptoms of psoriatic arthritis after 12 weeks, including American College of Rheumatology 20,Clinical Disease Activity Index, Disease Activity Index 28, Dactylitis and adverse events.
Condition: Psoriatic Arthritis | Phase: Phase 4 | Minimum Age: 18 Years